BB's Stock Haven

[legacyinvestor]

HTI has some great news this morning.

Halozyme Therapeutics Releases Results of Enhanze Technology Clinical Trial to Improve the Subcutaneous Absorption of a Large Protein Molecule Therapeutic.

"The findings from this first clinical trial of Enhanze Technology provide proof of concept that rHuPH20 may also have clinical application for large molecule therapeutics," said Richard C. Yocum, MD, Vice President of Clinical Development and Medical Affairs at Halozyme. "Additional studies with larger patient sample sizes are warranted to further characterize the rHuPH20 effect, especially with regard to optimal dose, and to investigate the role that rHuPH20 may play in addressing unmet needs in the administration of large molecule agents, thereby opening up new areas of therapeutic indications."